Printer Friendly

Bruhn Named Chief Executive Officer at Proclara Biosciences.

M2 PHARMA-April 27, 2017-Bruhn Named Chief Executive Officer at Proclara Biosciences

(C)2017 M2 COMMUNICATIONS

- US-based biotechnology company Proclara Biosciences has appointed Suzanne Bruhn, Ph.D., as president and chief executive officer, the company said.

Bruhn brings more than two decades of experience in the life sciences, with a strong track record of successfully developing and commercialising biologics.

She will serve as president and CEO, and join the board of directors of Proclara.

Bruhn most recently served as president and CEO of Promedior, Inc., where she successfully negotiated an exclusive agreement with Bristol Myers Squibb for the right to acquire Promedior for a total deal potential of USD 1.25bn.

Previously, she served as senior vice president of strategic planning and program management at Shire's Human Genetic Therapies division.

Bruhn serves on the board of directors of Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) and Pliant Therapeutics.

Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins.

The broad applicability of the Proclara technology enables the company to target multiple protein misfolding diseases, including neurodegenerative diseases and several rare systemic amyloidoses. The lead GAIM drug candidate, NPT088, is in clinical development for the treatment of Alzheimer's disease.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 27, 2017
Words:221
Previous Article:Axial Biotherapeutics Names Renaud, Wolf to Board of Directors.
Next Article:Avedro Raises USD 42m; Will Support Commercial Expansion, Pipeline Development.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters